I-Tech AB (ITECH.ST)
SEK 54.5
(-1.8%)
SEK 54.5
(-1.8%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 152.44 Million SEK | 21.56% |
| 2022 | 125.4 Million SEK | 8.93% |
| 2021 | 115.12 Million SEK | -4.21% |
| 2020 | 120.17 Million SEK | -8.49% |
| 2019 | 131.32 Million SEK | 6.31% |
| 2018 | 123.52 Million SEK | 106.13% |
| 2017 | 59.92 Million SEK | -1.38% |
| 2016 | 60.76 Million SEK | 23.16% |
| 2015 | 49.33 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 163.74 Million SEK | 10.2% |
| 2024 Q1 | 162.72 Million SEK | 6.74% |
| 2024 Q2 | 148.58 Million SEK | -8.69% |
| 2023 Q4 | 152.44 Million SEK | 0.21% |
| 2023 FY | 152.44 Million SEK | 21.56% |
| 2023 Q1 | 134.77 Million SEK | 7.47% |
| 2023 Q2 | 141.41 Million SEK | 4.93% |
| 2023 Q3 | 152.11 Million SEK | 7.57% |
| 2022 Q4 | 125.4 Million SEK | 2.27% |
| 2022 FY | 125.4 Million SEK | 8.93% |
| 2022 Q1 | 115.93 Million SEK | 0.71% |
| 2022 Q2 | 120.37 Million SEK | 3.82% |
| 2022 Q3 | 122.62 Million SEK | 1.87% |
| 2021 Q1 | 123.7 Million SEK | 2.93% |
| 2021 FY | 115.12 Million SEK | -4.21% |
| 2021 Q4 | 115.12 Million SEK | -5.54% |
| 2021 Q3 | 121.88 Million SEK | 0.88% |
| 2021 Q2 | 120.81 Million SEK | -2.33% |
| 2020 Q2 | 126.64 Million SEK | -1.95% |
| 2020 Q3 | 125.01 Million SEK | -1.28% |
| 2020 Q4 | 120.17 Million SEK | -3.87% |
| 2020 Q1 | 129.15 Million SEK | -1.65% |
| 2020 FY | 120.17 Million SEK | -8.49% |
| 2019 FY | 131.32 Million SEK | 6.31% |
| 2019 Q2 | 114.33 Million SEK | -4.71% |
| 2019 Q4 | 131.32 Million SEK | 11.92% |
| 2019 Q3 | 117.33 Million SEK | 2.63% |
| 2019 Q1 | 119.99 Million SEK | -2.86% |
| 2018 Q3 | 123.09 Million SEK | -8.1% |
| 2018 Q4 | 123.52 Million SEK | 0.35% |
| 2018 FY | 123.52 Million SEK | 106.13% |
| 2018 Q2 | 133.94 Million SEK | 46.65% |
| 2018 Q1 | 91.34 Million SEK | 52.42% |
| 2017 Q4 | 59.92 Million SEK | 0.0% |
| 2017 FY | 59.92 Million SEK | -1.38% |
| 2017 Q1 | - SEK | 0.0% |
| 2016 FY | 60.76 Million SEK | 23.16% |
| 2015 FY | 49.33 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -28.698% |
| Ziccum AB (publ) | 14.97 Million SEK | -918.187% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -660.656% |
| BioArctic AB (publ) | 1.18 Billion SEK | 87.147% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -144.39% |
| Mendus AB (publ) | 755.95 Million SEK | 79.834% |
| Genovis AB (publ.) | 288.85 Million SEK | 47.225% |
| Intervacc AB (publ) | 259.61 Million SEK | 41.28% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -263.314% |
| Active Biotech AB (publ) | 44 Million SEK | -246.461% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 45.311% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -145.274% |
| Aptahem AB (publ) | 63.02 Million SEK | -141.877% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 69.281% |
| Kancera AB (publ) | 65.64 Million SEK | -132.23% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 56.61% |
| Fluicell AB (publ) | 9.34 Million SEK | -1532.152% |
| Saniona AB (publ) | 64.14 Million SEK | -137.661% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -353.672% |
| Biovica International AB (publ) | 131.4 Million SEK | -16.007% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -187.71% |
| AcouSort AB (publ) | 34.51 Million SEK | -341.697% |
| Xintela AB (publ) | 18.39 Million SEK | -728.72% |
| Abliva AB (publ) | 87.49 Million SEK | -74.223% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 79.947% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 87.886% |
| OncoZenge AB (publ) | 20.34 Million SEK | -649.474% |
| Amniotics AB (publ) | 26.08 Million SEK | -484.386% |
| 2cureX AB (publ) | 16.62 Million SEK | -816.95% |
| CombiGene AB (publ) | 120.61 Million SEK | -26.391% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -2408.524% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 91.979% |
| Camurus AB (publ) | 1.9 Billion SEK | 92.01% |
| Corline Biomedical AB | 100.1 Million SEK | -52.283% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 13.933% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -8.425% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 85.026% |
| Cyxone AB (publ) | 43.65 Million SEK | -249.199% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -93.721% |
| Biosergen AB | 7.2 Million SEK | -2016.97% |
| Cantargia AB (publ) | 223.71 Million SEK | 31.857% |
| NextCell Pharma AB | 81.28 Million SEK | -87.534% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 80.08% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -405.229% |
| Nanologica AB (publ) | 77.42 Million SEK | -96.881% |
| SynAct Pharma AB | 228.01 Million SEK | 33.145% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -469.604% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -602.409% |
| LIDDS AB (publ) | 17.65 Million SEK | -763.455% |
| Lipum AB (publ) | 12.11 Million SEK | -1158.819% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 89.113% |
| Alzinova AB (publ) | 123.18 Million SEK | -23.747% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 36.05% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -1702.992% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -78.867% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -925.24% |
| Simris Alg AB (publ) | 174.55 Million SEK | 12.666% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 29.762% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 76.673% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -75.077% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -434.738% |